|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
310,240,000 |
Market
Cap: |
11.37(B) |
Last
Volume: |
1,994,274 |
Avg
Vol: |
2,362,196 |
52
Week Range: |
$20.34 - $39.155 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
425,000 |
735,409 |
Total Buy Value |
$0 |
$0 |
$8,733,955 |
$15,268,727 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
2 |
4 |
Total Shares Sold |
303,926 |
643,662 |
1,129,338 |
1,681,109 |
Total Sell Value |
$11,139,944 |
$22,648,413 |
$35,001,763 |
$46,750,740 |
Total People Sold |
10 |
11 |
13 |
14 |
Total Sell Transactions |
12 |
21 |
35 |
47 |
End Date |
2024-12-15 |
2024-09-13 |
2024-03-15 |
2023-03-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Haley Patrick J. |
EVP, Commercial |
• – – |
2025-03-03 |
4 |
AS |
$38.80 |
$388,000 |
D/D |
(10,000) |
341,028 |
|
-5% |
|
Wyszomierski Jack L |
Director |
– • – |
2025-02-28 |
4 |
AS |
$37.80 |
$331,430 |
D/D |
(8,768) |
356,605 |
|
-5% |
|
Wyszomierski Jack L |
Director |
– • – |
2025-02-28 |
4 |
OE |
$20.50 |
$325,417 |
D/D |
15,874 |
365,373 |
|
- |
|
Smith Julie |
Director |
– • – |
2025-02-28 |
4 |
S |
$37.62 |
$725,840 |
D/D |
(19,294) |
10,778 |
|
5% |
|
Smith Julie |
Director |
– • – |
2025-02-28 |
4 |
OE |
$19.77 |
$381,442 |
D/D |
19,294 |
30,072 |
|
- |
|
Smith Julie |
Director |
– • – |
2025-02-27 |
4 |
S |
$38.13 |
$2,078,619 |
D/D |
(54,514) |
10,778 |
|
2% |
|
Smith Julie |
Director |
– • – |
2025-02-27 |
4 |
OE |
$19.77 |
$1,100,494 |
D/D |
54,514 |
65,292 |
|
- |
|
Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
52,192 |
347,089 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
47,718 |
351,028 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
59,648 |
839,255 |
|
- |
|
Morrissey Michael M |
President and CEO |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
184,909 |
1,033,290 |
|
- |
|
Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
49,209 |
561,117 |
|
- |
|
Hessekiel Jeffrey |
EVP & General Counsel |
• – – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
52,192 |
597,608 |
|
- |
|
Oliver Bob |
Director |
– • – |
2025-02-25 |
4 |
S |
$37.25 |
$694,601 |
D/D |
(18,647) |
33,514 |
|
0% |
|
Oliver Bob |
Director |
– • – |
2025-02-25 |
4 |
OE |
$19.28 |
$292,034 |
D/D |
15,147 |
52,161 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
• – – |
2025-02-24 |
4 |
S |
$36.98 |
$1,946,479 |
D/D |
(52,636) |
303,310 |
|
1% |
|
Morrissey Michael M |
President and CEO |
• • – |
2025-02-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
177,985 |
1,764,985 |
|
- |
|
Morrissey Michael M |
President and CEO |
• • – |
2025-02-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
177,985 |
848,381 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
• – – |
2025-02-24 |
4 |
S |
$36.14 |
$1,059,408 |
D/D |
(29,314) |
779,607 |
|
1% |
|
Senner Christopher J. |
EVP and CFO |
• – – |
2025-02-24 |
4 |
OE |
$18.80 |
$551,103 |
D/D |
29,314 |
808,921 |
|
- |
|
Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2025-02-24 |
4 |
S |
$36.75 |
$991,772 |
D/D |
(26,987) |
511,908 |
|
1% |
|
Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2025-02-15 |
4 |
D |
$35.00 |
$1,006,180 |
D/D |
(28,748) |
538,895 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
• – – |
2025-02-15 |
4 |
D |
$35.00 |
$755,685 |
D/D |
(21,591) |
779,607 |
|
- |
|
Morrissey Michael M |
President and CEO |
• • – |
2025-02-15 |
4 |
D |
$35.00 |
$2,224,950 |
D/D |
(63,570) |
1,026,366 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
• – – |
2025-02-15 |
4 |
D |
$35.00 |
$661,710 |
D/D |
(18,906) |
355,946 |
|
- |
|
1076 Records found
|
|
Page 1 of 44 |
|
|